BRAF and colorectal carcinoma: In the GSE39582 dataset, BRAF mutation status was not associated with the 3-year OS rate (75.7% mutation (+) vs. 78.9%, mutation (−) p = 0.6, number of patients: 30 vs. 300) or DFS rate (73.6% mutation (−) vs. 71.1% mutation (−), p = 0.79, number of patients: 27 vs. 252) of all CRC patients (Figure 1).